Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Patients With Suspected Malignancies of the Pituitary Gland
and you are
over 18
years old
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

This study is focusing on patients presenting with suspected malignancies of the pituitary gland who are considered to be good surgical candidates.The primary end-point of the study is to determine the sensitivity of OTL38 uptake and expression in identifying those nodules when excited by an imaging probe.There will be a single dose of 0.025 mg/kg for intravenous injection over approximately 60 minutes, two to three hours, prior to surgery.

Provided treatments

  • Drug: OTL0038
  • Drug: Benadryl
  • Device: intraoperative imaging
Wondering what is the locations section for?
We will connect you to the doctor responsible for this trial and help you get more information.

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02769533. The sponsor of the trial is Abramson Cancer Center of the University of Pennsylvania and it is looking for 50 volunteers for the current phase.
Official trial title:
A Phase 1, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor-alpha Positive Pituitary Adenoma